Abstract RET (rearranged during transfection) tyrosine kinase is a promising target for several human cancers. Abt-348, Birb-796, Motesanib and Sorafenib are DFG-out multi-kinase inhibitors that have been reported to inhibit RET activity with good IC50 values. Although the DFG-out conformation has attracted great interest in the design of type II inhibitors, the structural requirements for binding to the RET DFG-out conformation remains unclear. Herein, the DFG-out conformation of RET was determined by homology modelling, the four inhibitors were docked, and the binding modes investigated by molecular dynamics simulation. Binding free energies were calculated using the molecular mechanics/Poisson-Bolzmann surface area (MM/PBSA) method. The trends in predicted binding free affinities correlated well with experimental data and were used to explain the activity difference of the studied inhibitors. Per-residue energy decomposition analyses provided further information on specific interaction properties. Finally, we also conducted a detailed e-pharmacophore modelling of the different RET-inhibitor complexes, explaining the common and specific pharmacophore features of the different complexes. The results reported herein will be useful in future rational design of novel DFG-out RET inhibitors. Graphical Abstract Left Ribbon representation of DFG-out RET tyrosine kinase structure showing key residues of RET interacting with inhibitors. Right e-Pharmacophore hypothesis for RET-Abt-348 generated from the complex structure
free energies       1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Thermodynamic_free_energy

pharmacophore                 1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Pharmacophore         

homology                      0.9993353780287992^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Homology_(biology)    

molecular mechanics           1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Molecular_mechanics   

simulation                    0.9690660797507171^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Computer_simulation   

RET                           0.9857771410713602^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Förster_resonance_energy_transfer

RET                           0.9857771410713602^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Förster_resonance_energy_transfer

inhibitors                    1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Enzyme_inhibitor      

transfection                  1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Transfection          

RET                           0.9857771410713602^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Förster_resonance_energy_transfer

RET                           0.9857771410713602^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Förster_resonance_energy_transfer

molecular dynamics            1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Molecular_dynamics    

conformation                  0.9999454353021301^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Protein_structure     

rational design               1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Drug_design           

hypothesis                    0.999999956408261^^http://www.w3.org/2001/XMLSchema#double            http://dbpedia.org/resource/Hypothesis            

complex structure             0.9999968539734174^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Complex_manifold      

tyrosine kinase               0.999999770341814^^http://www.w3.org/2001/XMLSchema#double            http://dbpedia.org/resource/Tyrosine_kinase       

tyrosine kinase               0.999999770341814^^http://www.w3.org/2001/XMLSchema#double            http://dbpedia.org/resource/Tyrosine_kinase       

II                            0.9999253870143516^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/World_War_II          

MM                            1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Molecular_mechanics   

energy                        0.9999977287480633^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Energy                

inhibitors                    1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Enzyme_inhibitor      

Sorafenib                     1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Sorafenib             

inhibitors                    1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Enzyme_inhibitor      

RET                           0.9857771410713602^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Förster_resonance_energy_transfer

inhibitors                    1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Enzyme_inhibitor      

inhibitors                    1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Enzyme_inhibitor      

conformation                  0.9999454353021301^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Protein_structure     

RET                           0.9857771410713602^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Förster_resonance_energy_transfer

inhibitors                    1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Enzyme_inhibitor      

residues                      0.9937167426691169^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Amino_acid            

cancers                       1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Cancer                

IC50                          1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/IC50                  

surface area                  0.9802179233878878^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Surface_area          

conformation                  0.9999454353021301^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Protein_structure     

decomposition                 0.9993333204404483^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Variance              

RET                           0.9857771410713602^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Förster_resonance_energy_transfer

